University of South Florida
Tampa, Florida, 33612, United States
Location status: Recruiting
NCT Number: NCT04896775
The goal of this project evaluate the efficacy of NiteCAPP in improving insomnia in a rural dementia caregiver sample (n of 100 caregiver and PWD dyads). We will measure both the short term (post-treatment) and long term (6 and 12 months) effects of the intervention on CG sleep, arousal, inflammation, health, mood, burden and cognitive function, and PWD sleep.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Tampa, Florida, 33612, United States
Location status: Recruiting
Over the next 30 years, more than 10 million persons living with dementia in the US will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers (CG) and persons with dementia (PWD) alike, but increases caregiver risk of insomnia and related negative health outcomes, including depression, anxiety, cognitive disturbances and poor quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is an effective and established evidence based treatment for adults of all ages. Although relatively understudied in dementia caregivers, the research suggests CBT-I is also efficacious in caregivers. Our team developed a brief (4 session) CBT-I protocol adapted for dementia caregivers and has shown in person and remote (i.e. telehealth) delivery of this protocol significantly reduces insomnia and improves mood (moderate to large effects). Given demands on caregiver time and limited availability of trained CBT-I providers, we developed a web-based version of this treatment (NiteCAPP) to increase accessibility of this efficacious treatment for rural dementia CGs. NiteCAPP will allow for flexible at home scheduling, and the skills needed to monitor caregiver treatment progress can be quickly and efficiently taught to healthcare providers. The Cognitive Activation Theory of Stress provides a framework for our basic premise that CGs experience insomnia, arousal and inflammation that prompt sympathetic activation and hypothalamic-pituitary-adrenal (HPA) disruption that have negative effects on health. The proposed trial tests the novel hypothesis that NiteCAPP will improve CG health, mood, burden and cognition by targeting their shared mechanisms - sleep, arousal and inflammation - thereby, returning sympathetic and HPA functioning to normal. Another novel aspect of the proposed trial is inclusion of behavioral strategies to target the PWD sleep. Objectives: The goal of this project evaluate the efficacy of NiteCAPP in improving insomnia in a rural dementia caregiver sample (n of 100 caregiver and PWD dyads). We will measure both the short term (post-treatment) and long term (6 and 12 months) effects of the intervention on CG sleep, arousal, inflammation, health, mood, burden and cognitive function, and PWD sleep.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Caregiver Eligibility. Inclusion criteria: 1. 18+ yrs, 2. CG living with PWD, 3. willing to be randomized, 4. read/understand English, 5. insomnia diagnosis, 6. no prescribed or over the counter sleep meds for 1+ mo, or stabilized 6+ mos.
PWD Eligibility. 1. probable/possible Alzheimer's Disease (self-report or primary care provider written confirm), 2. 1+ problem on Nighttime Behavior Inv. 3+ nts/wk, 3. tolerate actigraphy, 4. no sleep meds 1+ mo or stabilized 6+ mos, 5. untreated sleep disorder for which CBT-I is not recommended (e.g., apnea), 6. scoring <32 on Sleep Apnea scale, Sleep Disorders Ques.
Exclusion:
CG Exclusion criteria: 1. unable to consent, 2. cognitive impairment [Telephone Interview for Cognitive Status (TICS) <25], 3. sleep disorder other than insomnia [i.e., apnea (apnea/hypopnea index-AHI >15)], 4. bipolar or seizure disorder, 5. other major psychopathology except depression or anxiety (e.g., suicidal, psychotic), 6. severe untreated psychiatric comorbidity, 7. psychotropic or other medications (e.g., beta-blockers) that alter sleep, 8. non-pharmacological tx for sleep or mood outside current trial.
Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
Other names: Web CBT-I
Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
Other names: Web Sleep Hygiene and Related Education (Web-SHARE)
Time frame: Single administration at 8 weeks
Percentage of sessions completed out of the 4 sessions/modules included in NiteCAPP and WebSHE.
Time frame: Single administration at 8 weeks
Percentage of the intervention instructions followed as indicated on the treatment adherence logs completed each day during treatment.
Time frame: Single administration at 8 weeks
Questionnaire with 15 items, including two open-ended questions, that assesses the usability, like-ability, and usefulness of online interventions using a 5-point Likert scale from 1-not at all to 5-very. The two open-ended questions ask the participant to list the most and least helpful parts of the program
Time frame: Single administration at 8 weeks
Survey that assesses the patient's experience and satisfaction with treatment.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Brief self-report measure of current perception of insomnia symptom severity, distress and daytime impairment. Commonly used as an outcome assessment in insomnia treatment research.
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Completed each morning (~5 mins) during each assessment period. Electronic daily diaries collecting self-reported information on caregiver sleep onset latency (time to fall asleep), wake after sleep onset (time awake after sleep onset to last awakening), and sleep efficiency (total sleep time divided by time in bed and multiplied by 100). We developed and tested these electronic diaries.
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record pain intensity; range: 0-100 (no pain- most intense)
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record pain unpleasantness; range: 0-100 (none- most unpleasantness)
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record wake after sleep onset (number of minutes)
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record sleep onset latency (number of minutes)
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record sleep efficiency
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record insomnia severity; range: 0-100 (no insomnia - most severe)
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Daily electronic dairies will record daily medication consumption
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Perceived Stress Scale is a self-report measure of how life situations are perceived as stressful. The scale consists of 15 items corresponding to everyday situation and participants are asked to rate on a Likert scale from 0 (never) to 4 (very often) how
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
A 10-item scale that asks caregivers to rate on a scale from 1 (no stress) to 5 (extreme stress) how much stress they experience related to various aspects of caregiving.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
A self-report measure of sleep-related arousal. This measure consists of 30 questions intended to measure 5 dimensions: misconceptions about the causes of insomnia, misattributions or amplifications of the consequences, unrealistic expectations, control, and predictability of sleep and faulty beliefs about sleep promoting practices. Although the original scale used a 100 mm VAS, subsequent research with the DBAS has used an 11-point Likert scale (0 = strongly disagree, 10 = strongly agree), and the latter response method will be used.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Holter monitor assessed 5 min ECG recordings at rest at home (enhancing ecological validity). Variables: RMSDNN (root mean sqrd standard dev. of N-N intervals), pNN50 (percent of N-N intervals less than 50 ms), LF over HF (high frequency divided by low frequency ratio; index of autonomic nervous system regulation).
Time frame: Single blood draw at baseline, 8 weeks, 6 month and 12 follow up
Blood based biomarkers will be examined at each assessment period. Biomarkers include: inflammatory (HS-CRP, IL-6), neurodegenerative ( AβB42, tau levels)
Time frame: Single blood draw at baseline, 8 weeks, 6 month and 12 follow up
Inflammation
Time frame: Single blood draw at baseline, 8 weeks, 6 month and 12 follow up
Neurodegenerative
Time frame: Single blood draw at baseline, 8 weeks, 6 month and 12 follow up
Neurodegenerative
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Inventory that asks respondents to rate how true 20 self-descriptive statements (e.g., I feel calm) are on a 4-point scale (1 = not at all, 4 = very much so). Typically, respondents are asked to rate statements according to how they generally feel (trait-anxiety scale) and how they feel in the current moment (state-anxiety scale). Total scores range from 20 to 80, with higher scores indicating greater maladjustment.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
BDI contains 21 items that measure severity of depressive symptomatology on a three-point scale (0 = absence of symptoms, 3 = most severe). Respondents answer for the previous week. Total scores range from 0 to 63. Ranges for clinical levels of depression are 0 to 13 (minimal), 14 to 19 (mild), 20 to 28 (moderate), and 29 to 63 (severe).
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
The SF-36 is a 36-item scale that assesses health status and quality of life The SF-36 includes eight domains: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems); bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Participants respond based on how they have felt over the previous week. The items use Likert-type scales, some with 5 or 6 points and others with 2 or 3 points. The SF-36 is a sensitive indicator of CG mental and physical health.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Self-report measure of caregiver burden. 12-item scale that asks caregivers to rate from never (0) to nearly always (4) how often they experience feelings of stress or burden across various aspects and situations of caregiving.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
A 25-item scale measuring subjective cognition. Caregivers rate on a scale of 0 (never) to 4 (very often) how often they experience cognitive mistakes and errors in daily tasks.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
A 20-item questionnaire measuring the CG's quality of life.
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Wake after sleep onset via Actiwatch-2
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Sleep Onset Latency via Actiwatch-2
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Sleep Efficiency via Actiwatch-2
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Caregivers will complete this 20-min computerized battery in single sitting. Domains tested include processing speed and attention, visuospatial ability and memory, verbal learning and memory, and executive functioning and working memory. Cognitive domains tested are ones that research has shown are impacted by caregiving.
Time frame: Daily at baseline, 8 weeks, 6 month and 12 follow up
Completed each morning (~15-mins) for 7 days during each assessment period. Caregivers will complete this online neuropsychological battery. Practice effects limited by: 16 versions, randomized presentation order, and 12 or more wks before repeating any version. Domains tested include processing speed and attention, visuospatial ability and memory, verbal learning and memory, and executive functioning and working memory. Cognitive domains tested are ones that research has shown are impacted by caregiving. Daily testing enhances ecological validity.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
CG indicates the frequency and severity of 8 nighttime behaviors of the PWD (difficulty falling asleep, wandering during the night, etc.), as well as the level of emotional distress they experience associated with each behavior.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
CG rates severity of dementia across several domains: memory, speech and language, recognition of family members, orientation to place and time, ability to make decisions, social and community activity, home activities and responsibilities, personal care, eating, control or urination and bowels, ability to get from place to place. Higher scores indicate more severe dementia.
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
Questionnaire that assesses the stability of the CG/PWD dyad for 14 activities of daily living and instrumental activities of daily living. CG respondents indicate the patient's functional ability, whether the CG assists with the task, and whether the CG has emotional or physical difficulty assisting with the task
Time frame: Single administration at baseline, 8 weeks, 6 month and 12 follow up
This 4-item self-administered questionnaire assesses the number of times one engages in mild, moderate and strenuous LTPA bouts of at least 15 min duration in a typical week.
Time frame: Single administration at post-treatment - 8 weeks
Experience with the assessments, procedures, and other features of the research study; score range: 9-90 (low satisfaction - high satisfaction)
Contact information is provided by the study sponsor or research team.
University of South Florida
Other
NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers: Examination of Sleep, Arousal, Mood, Cognitive, and Immune Outcomes
Acronym: NiteCAPP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06093126
Brain Diseases, Central Nervous System Diseases
Halifax, Nova Scotia, Canada
View Trial DetailsNCT07363928
Brain Diseases, Central Nervous System Diseases
Cork, Ireland
View Trial DetailsNCT06854497
Apnea, Behavior
Chiayi City, Taiwan
View Trial DetailsNCT04141891
Acute Coronary Syndrome, Aortic Stenosis, Subvalvular
La Jolla, California, United States
View Trial Details